Rhythm Pharmaceuticals and LG Chem Enter into Amendment to Bivamelagon Exclusive License Agreement
-- Amendment revised royalty structure from low-to-mid-single digits to 1% on global net sales of Rhythm MC4R agonists, including setmelanotide, bivamelagon and RM-718 -- -- Rhythm to pay LG Chem additional fixed payments totaling $350 million over four years --
Covered in this story
Analyst targets on Rhythm Pharmaceuticals Inc
- H.C. Wainwright: $90.8 → $130 by Oct 2027 · Buy via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $RYTM yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Rhythm Pharmaceuticals Inc →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.